What is the share price of Nath Bio-Genes (I) Ltd (NATHBIOGEN) today?
The share price of NATHBIOGEN as on 2nd March 2026 is ₹143.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nath Bio-Genes (I) Ltd (NATHBIOGEN) share?
The past returns of Nath Bio-Genes (I) Ltd (NATHBIOGEN) share are- Past 1 week: -2.84%
- Past 1 month: -2.54%
- Past 3 months: -7.32%
- Past 6 months: -15.83%
- Past 1 year: -0.75%
- Past 3 years: -1.62%
- Past 5 years: -51.79%
What are the peers or stocks similar to Nath Bio-Genes (I) Ltd (NATHBIOGEN)?
The peers or stocks similar to Nath Bio-Genes (I) Ltd (NATHBIOGEN) include:What is the dividend yield % of Nath Bio-Genes (I) Ltd (NATHBIOGEN) share?
The current dividend yield of Nath Bio-Genes (I) Ltd (NATHBIOGEN) is 1.40.What is the market cap of Nath Bio-Genes (I) Ltd (NATHBIOGEN) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nath Bio-Genes (I) Ltd (NATHBIOGEN) is ₹271.85 Cr as of 2nd March 2026.What is the 52 week high and low of Nath Bio-Genes (I) Ltd (NATHBIOGEN) share?
The 52-week high of Nath Bio-Genes (I) Ltd (NATHBIOGEN) is ₹238.69 and the 52-week low is ₹136.What is the PE and PB ratio of Nath Bio-Genes (I) Ltd (NATHBIOGEN) stock?
The P/E (price-to-earnings) ratio of Nath Bio-Genes (I) Ltd (NATHBIOGEN) is 7.04. The P/B (price-to-book) ratio is 0.42.Which sector does Nath Bio-Genes (I) Ltd (NATHBIOGEN) belong to?
Nath Bio-Genes (I) Ltd (NATHBIOGEN) belongs to the Consumer Staples sector & Agro Products sub-sector.How to buy Nath Bio-Genes (I) Ltd (NATHBIOGEN) shares?
You can directly buy Nath Bio-Genes (I) Ltd (NATHBIOGEN) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nath Bio-Genes (I) Ltd
NATHBIOGEN Share Price
NSE₹143.054.68% (-7.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NATHBIOGEN Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
LowUndervalued compared to the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NATHBIOGEN Performance & Key Metrics
NATHBIOGEN Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 6.02 | 0.42 | 1.40% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 33.88 | 8.35 | 1.80% |
NATHBIOGEN Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NATHBIOGEN Company Profile
Nath Bio-Genes (India) is engaged in hybrid seed business and production, processing and marketing of hybrid and genetically modified (GM) seeds
GODREJAGRO
PE Ratio
27.21
27.21
1Y Return
15.35%
15.35%
Buy Reco %
100.00
100.00
PE Ratio
25.59
25.59
1Y Return
37.51%
37.51%
Buy Reco %
100.00
100.00
PE Ratio
84.79
84.79
1Y Return
245.97%
245.97%
Buy Reco %
0.00
0.00
GRMOVER
PE Ratio
54.36
54.36
1Y Return
112.15%
112.15%
Buy Reco %
0.00
0.00
MVKAGRO
PE Ratio
299.10
299.10
1Y Return
1,291.57%
1,291.57%
Buy Reco %
0.00
0.00
NATHBIOGEN Sentiment Analysis
NATHBIOGEN Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
NATHBIOGEN Stock Summary · November 2025
In the recent earnings call, management highlighted a resilient operational performance despite challenges such as erratic weather and the impact of illegal seeds on the market. Revenue for H1 FY '26 rose by 15.9%, driven by a richer product mix and strong demand, particularly in the vegetable seeds segment, which saw a remarkable 25% growth. While EBITDA margins faced compression due to increased customer credit, the company remains optimistic about future growth, projecting a 15% to 20% increase year-over-year. Strategic investments in R&D are set to enhance product innovation, particularly in hybrids that address climate challenges, positioning the company for sustained profitability and market expansion. Overall, a commitment to operational excellence and farmer engagement underscores a positive outlook amidst industry volatility.
NATHBIOGEN Stock Growth Drivers
NATHBIOGEN Stock Growth Drivers
8Stable Operational Performance
Nath Bio-Genes has demonstrated stable operational performance in the first half of FY '26, despite
Revenue and Profit Growth
In H1 FY '26, Nath Bio-Genes reported a revenue growth of 15.9% year-over-year, reaching INR
NATHBIOGEN Stock Challenges
NATHBIOGEN Stock Challenges
4Declining EBITDA Margins
The company is experiencing a decline in EBITDA margins, attributed to increased credit extended to
Seasonal Revenue Challenges
The company anticipates lower revenue growth in the second half of the year due to
NATHBIOGEN Forecast
NATHBIOGEN Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NATHBIOGEN
NATHBIOGEN
Income
Balance Sheet
Cash Flow
Quarterly Normal View
NATHBIOGEN Income Statement
NATHBIOGEN Income Statement
Quarterly Normal View
| Quarter | sep 2023 | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 22.63 | 34.27 | 44.40 | 244.01 | 32.27 | 37.35 | 56.37 | 287.53 | 47.85 | 70.38 | ||||||||||
Operating & Other expenses | 17.59 | 26.09 | 39.11 | 207.34 | 27.38 | 28.84 | 51.55 | 245.42 | 37.75 | 62.39 | ||||||||||
EBITDA | 5.04 | 8.18 | 5.29 | 36.67 | 4.89 | 8.51 | 4.82 | 42.11 | 10.10 | 7.99 | ||||||||||
| Depreciation/Amortization | 0.76 | 0.76 | 0.98 | 0.83 | 0.83 | 0.83 | 1.34 | 0.98 | 0.99 | 0.98 | ||||||||||
| PBIT | 4.28 | 7.42 | 4.31 | 35.84 | 4.06 | 7.68 | 3.48 | 41.13 | 9.11 | 7.01 | ||||||||||
| Interest & Other Items | 2.44 | 2.84 | 1.07 | 2.24 | 2.98 | 3.90 | 1.37 | 3.20 | 3.66 | 4.54 | ||||||||||
| PBT | 1.84 | 4.58 | 3.24 | 33.60 | 1.08 | 3.78 | 2.11 | 37.93 | 5.45 | 2.47 | ||||||||||
| Taxes & Other Items | 0.34 | 0.76 | 0.62 | 0.25 | -0.03 | 1.14 | 0.63 | 0.66 | 0.64 | 0.87 | ||||||||||
| Net Income | 1.50 | 3.82 | 2.62 | 33.35 | 1.11 | 2.64 | 1.48 | 37.27 | 4.81 | 1.60 | ||||||||||
| EPS | 0.86 | 2.02 | 1.87 | 17.49 | 0.53 | 1.33 | 0.42 | 19.58 | 2.53 | 0.84 |
NATHBIOGEN Company Updates
NATHBIOGEN Stock Peers
NATHBIOGEN Past Performance & Peer Comparison
NATHBIOGEN Past Performance & Peer Comparison
Comparing 3 stocks from
Consumer StaplesAgro Products
Compare valuation on Screener
Consumer StaplesAgro Products
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nath Bio-Genes (I) Ltd | 7.04 | 0.42 | 1.40% |
| Godrej Agrovet Ltd | 27.21 | 4.49 | 1.81% |
| Gujarat Ambuja Exports Ltd | 25.59 | 2.13 | 0.18% |
| Cian Agro Industries & Infrastructure Ltd | 84.79 | 1.73 | — |
NATHBIOGEN Stock Price Comparison
Compare NATHBIOGEN with any stock or ETFCompare NATHBIOGEN with any stock or ETF
NATHBIOGEN
NATHBIOGEN Holdings
NATHBIOGEN Shareholdings
NATHBIOGEN Promoter Holdings Trend
NATHBIOGEN Promoter Holdings Trend
NATHBIOGEN Institutional Holdings Trend
NATHBIOGEN Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NATHBIOGEN Shareholding Pattern
NATHBIOGEN Shareholding Pattern
NATHBIOGEN Shareholding History
NATHBIOGEN Shareholding History
Foreign Institutions
smallcases containing NATHBIOGEN stock
smallcases containing NATHBIOGEN stock
Looks like this stock is not in any smallcase yet.
NATHBIOGEN Events
NATHBIOGEN Events
NATHBIOGEN Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NATHBIOGEN Dividend Trend
No dividend trend available
NATHBIOGEN Upcoming Dividends
NATHBIOGEN Upcoming Dividends
No upcoming dividends are available
NATHBIOGEN Past Dividends
NATHBIOGEN Past Dividends
Cash Dividend
Ex DateEx DateAug 14, 2025
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 14, 2025
Cash Dividend
Ex DateEx DateAug 9, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 9, 2024
Cash Dividend
Ex DateEx DateJul 4, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 4, 2023
Cash Dividend
Ex DateEx DateJun 23, 2022
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jun 23, 2022
Cash Dividend
Ex DateEx DateAug 18, 2021
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 18, 2021
NATHBIOGEN Stock News & Opinions
NATHBIOGEN Stock News & Opinions
Articles & Videos
Earnings
Nath Bio-Genes (India) consolidated net profit declines 39.62% in the December 2025 quarter
Net profit of Nath Bio-Genes (India) declined 39.62% to Rs 1.60 crore in the quarter ended December 2025 as against Rs 2.65 crore during the previous quarter ended December 2024. Sales rose 78.90% to Rs 65.96 crore in the quarter ended December 2025 as against Rs 36.87 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales65.9636.87 79 OPM %5.4321.78 - PBDT0.764.62 -84 PBT-0.213.79 PL NP1.602.65 -40 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Nath Bio-Genes (India) to conduct board meeting
Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 31 January 2026.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Nath Bio-Genes (India) consolidated net profit rises 147.75% in the September 2025 quarter
Net profit of Nath Bio-Genes (India) rose 147.75% to Rs 2.75 crore in the quarter ended September 2025 as against Rs 1.11 crore during the previous quarter ended September 2024. Sales rose 36.22% to Rs 43.85 crore in the quarter ended September 2025 as against Rs 32.19 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales43.8532.19 36 OPM %13.9114.94 - PBDT4.381.91 129 PBT3.391.09 211 NP2.751.11 148 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Nath Bio-Genes (India) to declare Quarterly Results
Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Nath Bio-Genes (India) consolidated net profit rises 11.78% in the June 2025 quarter
Net profit of Nath Bio-Genes (India) rose 11.78% to Rs 37.28 crore in the quarter ended June 2025 as against Rs 33.35 crore during the previous quarter ended June 2024. Sales rose 16.33% to Rs 283.70 crore in the quarter ended June 2025 as against Rs 243.88 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales283.70243.88 16 OPM %13.4914.98 - PBDT36.8634.43 7 PBT35.8833.60 7 NP37.2833.35 12 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Nath Bio-Genes (India) to announce Quarterly Result
Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 11 July 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Nath Bio-Genes (India) to convene AGM
Nath Bio-Genes (India) announced that the 32th Annual General Meeting(AGM) of the company will be held on 22 August 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Board of Nath Bio-Genes (India) recommends final dividend
Nath Bio-Genes (India) announced that the Board of Directors of the Company at its meeting held on 29 April 2025, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.Powered by Capital Market - Live
10 months agoCapital Market - Live
Earnings
Nath Bio-Genes (India) consolidated net profit declines 43.51% in the March 2025 quarter
Net profit of Nath Bio-Genes (India) declined 43.51% to Rs 1.48 crore in the quarter ended March 2025 as against Rs 2.62 crore during the previous quarter ended March 2024. Sales rose 20.75% to Rs 51.97 crore in the quarter ended March 2025 as against Rs 43.04 crore during the previous quarter ended March 2024. For the full year,net profit declined 2.57% to Rs 38.60 crore in the year ended March 2025 as against Rs 39.62 crore during the previous year ended March 2024. Sales rose 9.71% to Rs 364.91 crore in the year ended March 2025 as against Rs 332.62 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales51.9743.04 21 364.91332.62 10 OPM %0.819.13 -13.6414.99 - PBDT2.913.27 -11 43.8641.38 6 PBT1.572.28 -31 40.0438.11 5 NP1.482.62 -44 38.6039.62 -3 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Nath Bio-Genes (India) to table results
Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 29 April 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant